KAPA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Kairos Pharma Ltd | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerKAPA

Market Cap10.5M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Kairos Pharma Ltd is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for ENV105 in Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105 (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
ENV105	Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105	n/a	Approved	Public pipeline row
KROS101	KROS101	n/a	Phase 1	Public pipeline row
KROS201	n/a	Cell Therapy	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

literature_publication | Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
literature_publication | A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.
literature_publication | Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
literature_publication | Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
literature_publication | First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).

Want the full KAPA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.